Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


OxyPharma adds clinics for its Rabeximod study

[Stockholm, Sweden, June 20, 2008.] Swedish drug development company OxyPharma has added clinics in two more countries to increase enrollment in its phase II clinical trial of Rabeximod, an orally administered compound for treatment of moderate or severe active Rheumatoid Arthritis (RA).

OxyPharma has received regulatory clearance to start enrollment of patients in clinics in Poland and Georgia, which brings the number of participating countries to nine. The company has also increased the number of clinics in some of the existing countries - Belgium, Bulgaria, Latvia, Lithuania, Romania, Serbia, and the UK. The objective is to increase enrollment and speed up the study. At present, approximately one third of the required number of patients (224) has started treatment.

OxyPharma's phase II trial of its immunomodulator, Rabeximod, is carried out in patients with moderate to severe active RA. The phase II study is done by Pharm-Olam International, a multi-national contract research organization. Principal Investigator is Prof. Lars Klareskog, Head of Rheumatology Unit at Karolinska Hospital, Stockholm, Sweden.

OxyPharma's primary objective is to evaluate the clinical response rate of Rabeximod when added to a stable dose of methotrexate in 224 patients with moderate or severe active RA. Rabeximod is given orally once daily for 12 weeks.

About OxyPharma:

OxyPharma is a Swedish drug development company developing new drugs primarily for the treatment of Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS). The development programs are carried out in collaboration with the Karolinska Institute in Stockholm, Sweden and contract research organizations (CRO's) in England, Sweden and Israel.

OxyPharma was founded in 2002 and is based in Stockholm, Sweden. The company's largest shareholder is innovator and entrepreneur Leif Lundblad (mainly through his investment company LLD Nybohov Invest). Ulf Björklund is OxyPharma's CEO.

For additional information please contact:

Ulf Björklund
CEO, OxyPharma AB
Phone: +46 8 726 17 02 or +46 70 667 04 40



Peter Karaszi
Press Officer, OxyPharma AB
Phone: +46 70 341 46 53


Also see our web site:

OxyPharma is a member of SwedenBIO. For more information about Swedish biotech, please visit

Publisher Contact Information:

OxyPharma AB
+46 8 726 17 02

Company profile of OxyPharma AB
Past press releases of OxyPharma AB.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Nov 8N/AOther Computers & Electronics
Nov 5€2.1MAudio/Video
Nov 5€5.2MOther Computers & Electronics
Nov 5€0.4MInternet services
Nov 5€1.3MSecurity
Nov 5€1.5MAudio/Video

For information on Europe's most extensive database on technology funding click here!


Press Releases

Sep 30
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.